Northwest Bancshares (FRA:NHS) Research & Development: €0.0 Mil (TTM As of Mar. 2026)


FRA:NHS Northwest Bancshares Inc FRA:NHS
55 GF Score
Price €12.80
GF Value €10.58
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Northwest Bancshares Research & Development?

Northwest Bancshares FRA:NHS +1.59% 55 Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:NHS with a GF Score™ of 55/100 and a GF Value™ of €10.58 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Northwest Bancshares's Research & Development for the three months ended in Mar. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Northwest Bancshares  (FRA:NHS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Northwest Bancshares Research & Development Related Terms

Northwest Bancshares Research & Development Historical Data

* Premium members only.

The historical data trend for Northwest Bancshares's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Bancshares Research & Development Chart

Northwest Bancshares Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Northwest Bancshares Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:NHS
55GF Score
Northwest Bancshares Inc FRA:NHS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Bancshares Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Northwest Bancshares (FRA:NHS) has a Research & Development of €0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Northwest Bancshares and its competitors.
Is Northwest Bancshares' Research & Development too high?
Northwest Bancshares' current Research & Development is €0.0 Mil. Overall, Northwest Bancshares has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Northwest Bancshares' Research & Development compare to BLX and LC?
Northwest Bancshares' Research & Development of €0.0 Mil can be compared against companies in the Banks industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Banks company?
A good Research & Development depends on the Banks industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Northwest Bancshares and its competitors. Northwest Bancshares's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Bancshares stock overvalued right now?
Based on GuruFocus' analysis, Northwest Bancshares (FRA:NHS) is currently considered Modestly Overvalued. The stock's GF Value™ is €10.58, compared to a current price of €12.80 — trading 21% above its estimated fair value. The current Research & Development is €0.0 Mil. Northwest Bancshares' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Northwest Bancshares (FRA:NHS), the current Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Northwest Bancshares (FRA:NHS) Overvalued in 2026?

Based on GuruFocus' analysis, Northwest Bancshares stock appears to be overvalued. The current stock price of €12.80 is trading 21% above its estimated GF Value™ of €10.58. GuruFocus considers Northwest Bancshares to be Modestly Overvalued.

Key valuation signals for FRA:NHS:

  • Research & Development: €0.0 Mil
  • GF Value™: €10.58 vs. price of €12.80 (21% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:NHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Northwest Bancshares Business Description

Other Exchanges NWBI:USA
Address 3 Easton Oval, Suite 500, Columbus, OH, USA, 43219
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
55GF Score

Get the complete analysis for FRA:NHS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.80
Price
€10.58
GF Value